Volume 58, Issue 4, Pages (April 2013)

Slides:



Advertisements
Similar presentations
Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.
Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Inflammasomes in liver diseases
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Volume 14, Issue 2, Pages (August 2011)
Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications  Sven M. Francque, Denise van der Graaff, Wilhelmus.
Pathological roles of purinergic signaling in the liver
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
The inflammasome in liver disease
Volume 17, Issue 6, Pages (June 2013)
Reactive oxygen species in the normal and acutely injured liver
Obesity, inflammation, and liver cancer
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 47, Issue 1, Pages (July 2007)
Vascular biology of metabolic syndrome
Obesity Heats Up Adipose Tissue Lymphocytes
Jean-Charles Nault, Jessica Zucman-Rossi  Journal of Hepatology 
Alcohol and toxicity Journal of Hepatology
The gut microbiota and the liver
Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute- on-chronic liver failure  Manuel Romero-Gómez, Sara Montagnese, Rajiv.
Hepatitis C virus entry and glucocorticosteroids
Living donor liver transplantation: is the hype over?
Volume 42, Issue 4, Pages (April 2005)
Mesenchymal stromal cell therapy for liver diseases
Gal3 Links Inflammation and Insulin Resistance
Volume 69, Issue 2, Pages (August 2018)
Ludger Scheja, Joerg Heeren  Journal of Hepatology 
Volume 44, Issue 4, Pages (April 2006)
Inflammation and portal hypertension – The undiscovered country
European Association for the Study of the Liver  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Signalling pathways in alcohol-induced liver inflammation
Targeting gut flora to prevent progression of hepatocellular carcinoma
Volume 7, Issue 6, Pages (June 2008)
Volume 54, Issue 5, Pages (May 2011)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 59, Issue 3, Pages (September 2013)
Volume 61, Issue 6, Pages (December 2014)
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Editorial II British Journal of Anaesthesia
Bridging immunity and lipid metabolism by gut microbiota
HCMV jogs the ‘memory’ of NK cells in HBV
Chengcheng Jin, Jorge Henao-Mejia, Richard A. Flavell  Cell Metabolism 
An Integrated View of Immunometabolism
The changing role of beta-blocker therapy in patients with cirrhosis
Cannabinoid signaling and liver therapeutics
Karel J. van Erpecum, Frank G. Schaap  Journal of Hepatology 
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
NASH animal models: Are we there yet?
Subhra K. Biswas, Raffaella Bonecchi  Cell Metabolism 
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Volume 142, Issue 4, Pages e6 (April 2012)
Volume 14, Issue 2, Pages (August 2011)
Manuel Hernández-Guerra, Anna Hadjihambi, Rajiv Jalan 
Pathogenesis of cholestatic hepatitis C
Risk factors and mechanisms of non-alcoholic steatohepatitis
Inflammatory pathways in alcoholic steatohepatitis
Adel Hammoutene, Pierre-Emmanuel Rautou  Journal of Hepatology 
Nathalie Ganne-Carrié, Pierre Nahon  Journal of Hepatology 
Shih-Yen Weng, Detlef Schuppan  Journal of Hepatology 
Sander Lefere, Frank Tacke  JHEP Reports 
NF-κB, Inflammation, and Metabolic Disease
Presentation transcript:

Volume 58, Issue 4, Pages 801-810 (April 2013) Non-alcoholic steatohepatitis: The role of oxidized low-density lipoproteins  Sofie M.A. Walenbergh, Ger H. Koek, Veerle Bieghs, Ronit Shiri-Sverdlov  Journal of Hepatology  Volume 58, Issue 4, Pages 801-810 (April 2013) DOI: 10.1016/j.jhep.2012.11.014 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Schematic diagram illustrating the metabolic crosstalk between liver, adipose tissue, gut, arteries and systemic inflammation. The development of NASH is dependent on underlying mechanisms related to the metabolic syndrome, such as disturbed intestinal permeability, gut microbiota, increased systemic inflammation, vascular abnormalities, and adipose tissue dysfunction as a result of increased macrophage infiltration and insulin resistance. In turn, NASH by itself can exacerbate inflammation in these metabolic tissues, retaining a positive feedback mechanism. Journal of Hepatology 2013 58, 801-810DOI: (10.1016/j.jhep.2012.11.014) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Schematic illustration showing the involvement of oxLDL in the macrophage inflammatory response. Lipid-laden foamy macrophages express higher levels of the scavenger receptors CD36 and SR-A and produce more pro-inflammatory cytokines. Through interplay with surrounding cells, these cytokines further amplify the inflammatory response. Blocking macrophage uptake of oxLDL leads to macrophages smaller in size, less CD36 and SR-A expression and reduced inflammation. Modified from [135], reprinted by permission from Elsevier. Journal of Hepatology 2013 58, 801-810DOI: (10.1016/j.jhep.2012.11.014) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions